Status: Recruiting
Novel Triple-dose Tuberculosis Retreatment Regimen
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent Tuberculosis (TB).
Participants needed: 370
Trial details
Phase: Phase 3Biological sex: AllType: InterventionalSponsor: Institute of Tropical Medicine, BelgiumUpdated: Apr 13, 2025Locations: 1
Eligibility criteria
All newly registered patients with smear-positive recurrent pulmonary TB [+3]
All patients with TB initially resistant to rifampicin on Xpert MTB/RIF testing [+5]